{"id":3920,"date":"2019-04-22T07:01:00","date_gmt":"2019-04-22T07:01:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=3920"},"modified":"2024-05-02T11:10:28","modified_gmt":"2024-05-02T09:10:28","slug":"the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/","title":{"rendered":"The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Rodr%C3%ADguez-Lago+I&amp;cauthor_id=31518013\">Iago Rodr\u00edguez-Lago<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-1\">1<\/a>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-2\">2<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ben%C3%ADtez+JM&amp;cauthor_id=31518013\">Jos\u00e9 M Ben\u00edtez<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-3\">3<\/a>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-4\">4<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Sempere+L&amp;cauthor_id=31518013\">Laura Sempere<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-5\">5<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=S%C3%A1ez-Gonz%C3%A1lez+E&amp;cauthor_id=31518013\">Esteban S\u00e1ez-Gonz\u00e1lez<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-6\">6<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Barreiro-de+Acosta+M&amp;cauthor_id=31518013\">Manuel Barreiro-de Acosta<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-7\">7<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=de+Z%C3%A1rate+JO&amp;cauthor_id=31518013\">Jone O de Z\u00e1rate<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-8\">8<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Cabriada+JL&amp;cauthor_id=31518013\">Jos\u00e9 L Cabriada<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-1\">1<\/a>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/#affiliation-2\">2<\/a><\/sup> , J Clin Apher 2019 Dec;34(6):680-685.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Objectives:\u00a0<\/strong>To assess the effectiveness and safety of combining granulocyte-monocyte apheresis (GMA) and vedolizumab (VDZ) in patients with refractory ulcerative colitis (UC). <strong>Methods:\u00a0<\/strong>This retrospective, multicentre pilot study included all UC patients receiving both GMA and VDZ. We recorded data on GMA sessions, demographic characteristics, and clinical response. Effectiveness was assessed 1 and 6 months after finishing the GMA using the partial Mayo score, C-reactive protein, and fecal calprotectin levels. Data were also compiled on VDZ intensification, use of new immunomodulators and colectomy during follow-up. <strong>Results:\u00a0<\/strong>Eight patients were included (mean age 46 years; 63% female; mean disease duration, 132 months; 50% E3). GMA was started after a loss of response to VDZ in all cases (25% primary nonresponse and 75% secondary loss of response). All had previously received anti-TNF agents. VDZ was prescribed as the second-, third-, or fourth-line biologic in 37%, 50%, and 13% of cases, respectively. Patients had a mean baseline partial Mayo score of 7.5 (SD 2.1) and received a median of 15 GMA sessions (range 5-38). After a median follow-up of 7.5 months (IQR 5-12), partial Mayo score decreased after 1 and 6 months (P = .01 and .06, respectively). Three patients (38%) achieved steroid-free clinical remission and five (63%) withdrew VDZ. Colectomy rate was 38%. No adverse events were observed during the combination therapy. <strong>Conclusions:\u00a0<\/strong>This small case series suggests that combining GMA with VDZ could be a treatment option in selected cases of UC with an inadequate response to this biologic agent.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Iago Rodr\u00edguez-Lago&nbsp;1&nbsp;2,&nbsp;Jos\u00e9 M Ben\u00edtez&nbsp;3&nbsp;4,&nbsp;Laura Sempere&nbsp;5,&nbsp;Esteban S\u00e1ez-Gonz\u00e1lez&nbsp;6,&nbsp;Manuel Barreiro-de Acosta&nbsp;7,&nbsp;Jone O de Z\u00e1rate&nbsp;8,&nbsp;Jos\u00e9 L Cabriada&nbsp;1&nbsp;2 , J Clin Apher 2019 Dec;34(6):680-685. Objectives:\u00a0To assess the effectiveness and safety of combining granulocyte-monocyte apheresis (GMA) and vedolizumab (VDZ) in patients with refractory ulcerative colitis (UC). Methods:\u00a0This retrospective, multicentre pilot study included all UC patients receiving both GMA and VDZ. We [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[310,66],"class_list":["post-3920","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-elderly","scientific_tags-vedolizumab"],"acf":{"sc_authors":"<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/31518013\/<\/a>"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Iago Rodr\u00edguez-Lago&nbsp;1&nbsp;2,&nbsp;Jos\u00e9 M Ben\u00edtez&nbsp;3&nbsp;4,&nbsp;Laura Sempere&nbsp;5,&nbsp;Esteban S\u00e1ez-Gonz\u00e1lez&nbsp;6,&nbsp;Manuel Barreiro-de Acosta&nbsp;7,&nbsp;Jone O de Z\u00e1rate&nbsp;8,&nbsp;Jos\u00e9 L Cabriada&nbsp;1&nbsp;2 , J Clin Apher 2019 Dec;34(6):680-685. Objectives:\u00a0To assess the effectiveness and safety of combining granulocyte-monocyte apheresis (GMA) and vedolizumab (VDZ) in patients with refractory ulcerative colitis (UC). Methods:\u00a0This retrospective, multicentre pilot study included all UC patients receiving both GMA and VDZ. We [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T09:10:28+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/\",\"name\":\"The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2019-04-22T07:01:00+00:00\",\"dateModified\":\"2024-05-02T09:10:28+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/","og_locale":"es_ES","og_type":"article","og_title":"The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? - Adacyte","og_description":"Iago Rodr\u00edguez-Lago&nbsp;1&nbsp;2,&nbsp;Jos\u00e9 M Ben\u00edtez&nbsp;3&nbsp;4,&nbsp;Laura Sempere&nbsp;5,&nbsp;Esteban S\u00e1ez-Gonz\u00e1lez&nbsp;6,&nbsp;Manuel Barreiro-de Acosta&nbsp;7,&nbsp;Jone O de Z\u00e1rate&nbsp;8,&nbsp;Jos\u00e9 L Cabriada&nbsp;1&nbsp;2 , J Clin Apher 2019 Dec;34(6):680-685. Objectives:\u00a0To assess the effectiveness and safety of combining granulocyte-monocyte apheresis (GMA) and vedolizumab (VDZ) in patients with refractory ulcerative colitis (UC). Methods:\u00a0This retrospective, multicentre pilot study included all UC patients receiving both GMA and VDZ. We [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T09:10:28+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/","name":"The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2019-04-22T07:01:00+00:00","dateModified":"2024-05-02T09:10:28+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/the-combination-of-granulocyte-monocyte-apheresis-and-vedolizumab-a-new-treatment-option-for-ulcerative-colitis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/3920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=3920"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=3920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}